Evidence map›Paper›PMID 36157449›Full record

ReviewFrontiers in endocrinology2022

Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review.

Yan Yang, Zhengtao Chen, Xiaoyan Zhao, Hongyan Xie, Lian Du, Hong Gao, Chunguang Xie

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Insights into the Therapeutic Use ofPharmaceuticals (Basel, Switzerland) · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Antidiabetic potential ofFrontiers in pharmacology · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan YangHospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, China.
Zhengtao ChenHospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, China.
Xiaoyan ZhaoHospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, China.
Hongyan XieHospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, China.
Lian DuSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Hong GaoHospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, China.
Chunguang XieHospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity-insulin resistance-β-cells apoptosis" is an important trilogy of the pathogenesis of type 2 diabetes. With the global pandemic of obesity and diabetes, continuous research and development of new drugs focuses on the prevention of the pathological progress of these diseases. According to a recent study, the natural product kaempferol has excellent antidiabetic effects. Therefore, this review comprehensively summarized the frontier studies and pharmacological mechanisms of kaempferol in the treatment of diabetes. The successful research and development of kaempferol may yield a significant leap in the treatment of diabetes and its complications.

Indexed as

Biological ProductsDiabetes Mellitus, Type 2HumansHypoglycemic AgentsKaempferolsObesityBiological ProductsHypoglycemic AgentsKaempferolsdiabetesdiabetes complicationskaempferolmechanismobesity

Identifiers

PMID36157449
PMCPMC9490412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.